“As AI continues to refine the blueprint of life, the fusion of Bioinformatics and Artificial intelligence will remain at the heart of personalized medicine, drug discovery, and genomic research, shaping the future of global healthcare”, Says Mr. Srinivas Thirunagari, Founder and CEO of Karyon Bio, California, USA, during an invited talk entitled “”AI, Bioinformatics and the future of Healthcare: Innovations and Opportunities”, organized by the Department of Computational and Systems Biology, School of Life Sciences, in association with the Federation of Asian Biotech Associations (FABA) on 4th February 2025.
Mr. Thirunagari’s insightful talk deliberated on the transformative role of Artificial Intelligence (AI) and Bioinformatics in revolutionizing modern healthcare. He emphasized how AI-driven innovations are shaping precision medicine, diagnostics, and treatment strategies, enabling early disease detection and personalized healthcare solutions.
As the CEO of Karyon Bio, Mr. Thirunagari introduced the company’s ground breaking Digital Liver initiative, an AI-powered approach to tackling Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). By integrating multi-omics data, deep learning, and advanced imaging techniques, Karyon Bio is at the forefront of non-invasive diagnostics and biomarker discovery, paving the way for more effective liver disease management.
He also highlighted AI’s expanding role in biomarker discovery, drug research, and clinical decision-making, powered by advances in Large Language Models (LLMs), deep learning, and multimodal AI systems. He encouraged students and researchers to hone skills in coding, AI, and data science, underscoring India’s potential to be a global leader in Bioinformatics-driven healthcare solutions.
Mr. Thirunagari’s address served as a call to action for the next generation to embrace AI and Bioinformatics, driving innovation in precision medicine, drug discovery, and personalized healthcare.